Electroacupuncture Waveforms for Subacute Peripheral Facial Paralysis
low-frequency continuous wave EA
+ discontinuous wave EA
+ dilatational wave EA
Cranial Nerve Diseases+12
+ DNA Virus Infections
+ Facial Nerve Diseases
Treatment Study
Summary
Study start date: November 15, 2024
Actual date on which the first participant was enrolled.This study aims to explore the effectiveness of electroacupuncture with different waveforms in treating subacute peripheral facial paralysis. The trial involves seventy-five patients who will be treated at outpatient clinics in three hospitals in China. Participants will be divided into three groups, each receiving a specific type of electroacupuncture waveform: low frequency continuous, discontinuous, and dilatational waves. The study is important because it seeks to identify the most effective waveform, potentially leading to better treatment options for people experiencing facial paralysis, which can significantly affect their quality of life. Participants in the study will receive traditional acupuncture at specific points on the face and additional electroacupuncture treatment for 20 minutes, three times a week, over four weeks. The effectiveness of the treatments will be assessed using the Facial Nerve Grading System 2.0 at the start and end of the four-week period. Secondary measures include the Sunnybrook facial grading system, the Facial Disability Index Scale, and an amplitude ratio test of the affected and healthy sides using ENoG. These assessments will help determine improvements in facial movement and disability. The study will provide insights into the potential benefits and effectiveness of different electroacupuncture waveforms for facial paralysis treatment.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.75 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.From 18 to 65 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.3 intervention groups are designated in this study
This study does not include a placebo group
Treatment Groups
Group I
ExperimentalGroup II
ExperimentalGroup III
ExperimentalStudy Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
The Third Affiliated hospital of Zhejiang Chinese Medical University
Hangzhou, ChinaOpen The Third Affiliated hospital of Zhejiang Chinese Medical University in Google Maps